A Phase 3 interventional study of Ustekinumab in Crohn Disease, sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing ustekinumab in Crohn Disease — 3 open to participants now, 5 under way, 2 of them phase 3. Ustekinumab · Crohn Disease.
Among the 21 studies testing ustekinumab in Crohn Disease, this one is the 13th largest by enrollment, is one of 2 that started in 2020, is one of 8 in phase 3, and was the 12th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →3 of the 21 studies testing ustekinumab in Crohn Disease are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–70
By country, each count listing its studies:
Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 9 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 131 across the 21 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW has 4 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
3 of the studies testing ustekinumab in Crohn Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT06520397Sixth Affiliated Hospital, Sun Yat-sen UniversityEfficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | 2026-12-31 |
| NCT07303686McGill University Health Centre/Research Institute of the McGill University Health CentreDe-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing ustekinumab in Crohn Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to investigate the effect of re-induction with ustekinumab ≈6mg/kg IV followed by two different maintenance dosing regimens 90 mg subcutaneous every 8 weeks (Q8W) vs 90 mg subcutaneous every 4 weeks(Q4W) on clinical, biological and pharmacological outcomes in patients with Crohn's disease who show a secondary loss of response over time
The study is a prospective double blind interventional study in patients with Crohn Disease treated with ustekinumab that show an objective secondary loss of response to ustekinumab after induction treatment (>Week 16). Patients can be screened during a four week period. The screening includes a clinical, biochemical and endoscopic assessment. Patients will be randomized 8 weeks after the last subcutaneous injection with ustekinumab. All patient will receive an intravenous re-induction with ustekinumab ≈6mg/kg at baseline (8 weeks after last subcutaneous administration). After the intravenous re-induction, the patients receive either ustekinumab 90 mg subcutaneous Q4W or Q8W (altered with q8w placebo to mimic Q4W injections) till week 48. Clinical and biochemical evaluation will be planned every 8 weeks until week 36 with a final evaluation at week48. Primary endpoint will be assessed at week 48. Final assessment at week 48 will include clinical, biochemical and endoscopic evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. A documented decrease in biomarkers based on a value during induction period compared to a value prior to ustekinumab induction (max. 3 months prior to start of ustekinumab induction)
a. A decrease in CRP OR b. A decrease in FCP 2. A documented endoscopic improvement (evaluation during the induction period compared to an evaluation prior to ustekinumab induction (max. 6 months prior to start of ustekinumab induction) 6. Documented loss of response after induction (at any timepoint after week 16) assessed by the physician as moderate to severe active Crohn's disease. The increase in symptoms reported by the patient is defined as Patient Reported Outcome-2 (Abdominal Pain > 1 AND Stool Frequency > 3) AND confirmed by either any of the following* :
Documentation of endoscopic lesions in at least one segment of the ileum or colon as assessed by ileocolonoscopy AND a documented increase in biomarkers based on an increased value compared to the lowest value obtained during induction or after week 16 ustekinumab induction
7. Adequate in female of reproductive age (oral contraception, intra uterine device, sterilisation or barrier method) 8. Have the capacity to understand and sign an form. 9. Be able to adhere to the study visit schedule and other protocol requirements.
10. All Crohn's Disease treatments stable for at least 2 weeks prior to baseline.
* the criterium used to proof loss of response does not have to be identical to the one used to proof primary response : e.g. one can use an increase in biomarkers to proof primary response and a relapse on endoscopy to proof loss of response
Exclusion Criteria:
Ongoing treatment with
Have screening laboratory test results within the following parameters:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
Drug: Ustekinumab
re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
Drug: Ustekinumab
re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
Also known as: dose escalation only in arm 2
Proportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48
Proportion of patients with steroid free clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) and fecal calprotectin\<250µg/g at week 48. \[stool frequency (ST): average number of liquid stools for 1 week abdominal pain (AP): average scoring for abdominal pain for 1 week (0=none; 1=mild, 2=moderate; 3= severe)\]
Time frame: week 48
Proportion of Patients With Complete Endoscopic Remission at Week 48
Proportion of patients with complete endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD )\<3) at week 48
Time frame: week 48
Proportion of Patients With Endoscopic Remission at Week 48
Proportion of patients with endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD) \<5) at week 48
Time frame: week 48
Proportion of Patients With Endoscopic Response at Week 48
Proportion of patients with endoscopic response (≥50% decrease in simple endoscopic score for Crohn's disease (SES-CD)) at week 48
Time frame: week 48
Proportion of Patients With Clinical Remission at Week 8
Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 8
Time frame: week 8
Proportion of Patients With Clinical Remission at Week 48
Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 48
Time frame: week 48
Proportion of Patients With Biomarker Remission at Week 48
Proportion of patients with biomarker remission (C-reactive protein \<5 mg/L and fecal calprotectin \<250 µg/g) at week 48
Time frame: week 48
Proportion of Patients With Serious Adverse Events at Week 48
Proportion of patients with serious adverse events at week 48
Time frame: Week 48
Between February 2020 and October 2023 a total of 132 patients were screened and 108 patients were randomized. First Patient In (FPI) was on 11Mar2020. Last Patient In (LPI) was on 17Oct2023. Last Patient Out (LPO) was on 25Sep2024.
| Milestone | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Started | 54 | 54 |
| Completed | 37 | 35 |
| Not completed | 17 | 19 |
Proportion of patients with steroid free clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) and fecal calprotectin\<250µg/g at week 48. \[stool frequency (ST): average number of liquid stools for 1 week abdominal pain (AP): average scoring for abdominal pain for 1 week (0=none; 1=mild, 2=moderate; 3= severe)\]
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48 | 8 | 10 |
Proportion of patients with complete endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD )\<3) at week 48
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Complete Endoscopic Remission at Week 48 | 4 | 3 |
Proportion of patients with endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD) \<5) at week 48
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Endoscopic Remission at Week 48 | 15 | 8 |
Proportion of patients with endoscopic response (≥50% decrease in simple endoscopic score for Crohn's disease (SES-CD)) at week 48
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Endoscopic Response at Week 48 | 12 | 8 |
Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 8
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Clinical Remission at Week 8 | 19 | 21 |
Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 48
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Clinical Remission at Week 48 | 16 | 18 |
Proportion of patients with biomarker remission (C-reactive protein \<5 mg/L and fecal calprotectin \<250 µg/g) at week 48
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Biomarker Remission at Week 48 | 18 | 13 |
Proportion of patients with serious adverse events at week 48
| Participants | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| Proportion of Patients With Serious Adverse Events at Week 48 | 9 | 7 |
Collected over From signature of informed consent form up to week 48 in the study. For SAE's up to 60 days after the last study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ustekinumab q4w | 0/54 (0%) | 9/54 (16.7%) | 44/54 (81.5%) |
| Ustekinumab q8w | 0/54 (0%) | 7/54 (13%) | 46/54 (85.2%) |
| Event | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| (sub)obstructionGastrointestinal disorders | 3/54 | 1/54 |
| Abdominal painGastrointestinal disorders | 0/54 | 2/54 |
| Flare of Crohn's DiseaseGastrointestinal disorders | 2/54 | 0/54 |
| abdominal pain after right hemicolectomyInjury, poisoning and procedural complications | 0/54 | 1/54 |
| Cardiac AblationSurgical and medical procedures | 1/54 | 0/54 |
| Laparoscopic right hemicolectomySurgical and medical procedures | 0/54 | 1/54 |
| Extensive colitisGastrointestinal disorders | 1/54 | 0/54 |
| gastro-enteritisGastrointestinal disorders | 0/54 | 1/54 |
| Small bowel ileusGastrointestinal disorders | 0/54 | 1/54 |
| Bowel obstruction terminal ileitisGastrointestinal disorders | 1/54 | 0/54 |
| Event | Ustekinumab q4w | Ustekinumab q8w |
|---|---|---|
| respiratory infectionInfections and infestations | 21/54 | 25/54 |
| musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 18/54 | 22/54 |
| lab abnormalities/deficienciesMetabolism and nutrition disorders | 10/54 | 15/54 |
| Abdominal painGastrointestinal disorders | 10/54 | 13/54 |
| Skin abnormalitiesSkin and subcutaneous tissue disorders | 6/54 | 9/54 |
| fatigueGeneral disorders | 8/54 | 5/54 |
| fluInfections and infestations | 7/54 | 8/54 |
| headacheNervous system disorders | 5/54 | 7/54 |
| Worsening of Crohn's DiseaseGastrointestinal disorders | 6/54 | 4/54 |
| psychiatric symptomsPsychiatric disorders | 5/54 | 3/54 |
| Age, Continuous(years) | Ustekinumab q4w | Ustekinumab q8w | Total |
|---|---|---|---|
| Median | 41 (32 to 57) | 40 (32 to 53) | 41 (32 to 54) |
| Sex: Female, Male(Participants) | Ustekinumab q4w | Ustekinumab q8w | Total |
|---|---|---|---|
| Female | 35 | 32 | 67 |
| Male | 19 | 22 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Ustekinumab q4w | Ustekinumab q8w | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 54 | 54 | 108 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Sep 2024, 54 months.
Results were first posted in Apr 2026, 1 year 6 months after primary completion.
Of 88 phase 3 interventional studies under Crohn Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 69. This study's 54 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ustekinumab
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW